Pharmacokinetic‐tailored approach to hemophilia prophylaxis: Medical decision making and outcomes-Reference-Cited by-同舟云学术

Pharmacokinetic‐tailored approach to hemophilia prophylaxis: Medical decision making and outcomes

Published:2020-02 Issue:2 Volume:4 Page:326-333
ISSN:2475-0379
Container-title:Research and Practice in Thrombosis and Haemostasis
language:en
Short-container-title:Res Pract Thromb Haemost

Author:

Croteau Stacy E.¹^ORCID,Wheeler Allison P.²,Khan Osman³,Haley Kristina M.⁴,Borst Alexandra J.⁵,Lattimore Susan⁴,Yeung Cindy H. T.⁶,Iorio Alfonso⁶⁷^ORCID

Affiliation:

1. Boston Children's Hospital Boston Massachusetts

2. Department of Pathology, Microbiology & Immunology Vanderbilt University Medical Center Nashville Tennessee

3. University of Oklahoma Health Sciences Center Oklahoma City Oklahoma

4. The Hemophilia Center at Oregon Health & Science University Portland Oregon

5. Monroe Carell Jr. Children's Hospital at Vanderbilt Nashville Tennessee

6. Department of Health Research Methods, Evidence, and Impact McMaster University Hamilton ON Canada

7. Department of Medicine McMaster University Hamilton ON Canada

Funder

Advancing Science through Pfizer Investigator research exchange (ASPIRE) investigator-initiated research grant

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/rth2.12305

Reference28 articles.

1. Using pharmacokinetics to individualize hemophilia therapy

2. Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play?

3. Economic costs of hemophilia and the impact of prophylactic treatment on patient management;Chen SL;Am J Manag Care,2016

4. Predicting dose sparing benefit and bleeding risk of pharmacokinetic-based personalized prophylactic dosing of factor VIII products

5. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting joint involvement through tailored prophylaxis in severe haemophilia A, is it possible?;Haemophilia;2024-04-04

2. Letter to the Editor Regarding “Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China”;Advances in Therapy;2024-02-10

3. The road to implementation of pharmacokinetic-guided dosing of factor replacement therapy in hemophilia and allied bleeding disorders. Identifying knowledge gaps by mapping barriers and facilitators;Blood Reviews;2023-09

4. “A personalized limited sampling approach to better estimate terminal half‐life of FVIII concentrates”: Comment from Huang et al.;Journal of Thrombosis and Haemostasis;2022-10

5. The Impact of Pharmacokinetic-Guided Prophylaxis on Clinical Outcomes and Healthcare Resource Utilization in Hemophilia A Patients: Real-World Evidence from the CHESS II Study;Journal of Blood Medicine;2022-09